Q1 EPS Forecast for Merit Medical Systems Cut by Analyst

Merit Medical Systems, Inc. (NASDAQ:MMSI - Free Report) - Research analysts at Zacks Research decreased their Q1 2025 earnings per share (EPS) estimates for shares of Merit Medical Systems in a note issued to investors on Tuesday, March 18th. Zacks Research analyst I. Bandyopadhyay now anticipates that the medical instruments supplier will post earnings of $0.76 per share for the quarter, down from their prior forecast of $0.81. The consensus estimate for Merit Medical Systems' current full-year earnings is $3.37 per share. Zacks Research also issued estimates for Merit Medical Systems' Q2 2025 earnings at $0.96 EPS, Q4 2025 earnings at $1.02 EPS, Q1 2026 earnings at $0.74 EPS, Q2 2026 earnings at $1.08 EPS, Q3 2026 earnings at $1.10 EPS, Q4 2026 earnings at $1.15 EPS and FY2027 earnings at $4.34 EPS.

Several other research analysts also recently weighed in on MMSI. Barrington Research decreased their price target on shares of Merit Medical Systems from $115.00 to $111.00 and set an "outperform" rating on the stock in a research report on Wednesday, February 26th. Needham & Company LLC decreased their target price on Merit Medical Systems from $122.00 to $116.00 and set a "buy" rating on the stock in a report on Wednesday, February 26th. Piper Sandler reissued an "overweight" rating and set a $116.00 price target (up previously from $114.00) on shares of Merit Medical Systems in a report on Wednesday, January 29th. Wells Fargo & Company decreased their price objective on Merit Medical Systems from $120.00 to $117.00 and set an "overweight" rating on the stock in a research note on Wednesday, February 26th. Finally, Canaccord Genuity Group lowered their price objective on Merit Medical Systems from $128.00 to $127.00 and set a "buy" rating on the stock in a research report on Wednesday, February 26th. Two research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $110.78.

Remove Ads

Merit Medical Systems Stock Performance

Shares of MMSI traded up $3.00 on Thursday, reaching $104.68. The company's stock had a trading volume of 523,640 shares, compared to its average volume of 424,537. The stock's 50 day simple moving average is $104.11 and its two-hundred day simple moving average is $100.87. The company has a debt-to-equity ratio of 0.57, a current ratio of 5.36 and a quick ratio of 3.82. The stock has a market capitalization of $6.16 billion, a P/E ratio of 51.31, a PEG ratio of 2.34 and a beta of 0.91. Merit Medical Systems has a 12-month low of $70.70 and a 12-month high of $111.45.

Institutional Investors Weigh In On Merit Medical Systems

Several large investors have recently bought and sold shares of the business. NewSquare Capital LLC bought a new stake in shares of Merit Medical Systems in the 4th quarter worth about $32,000. Kohmann Bosshard Financial Services LLC purchased a new position in Merit Medical Systems in the fourth quarter worth about $52,000. Federated Hermes Inc. increased its stake in Merit Medical Systems by 139.1% during the fourth quarter. Federated Hermes Inc. now owns 655 shares of the medical instruments supplier's stock worth $63,000 after acquiring an additional 381 shares during the last quarter. Group One Trading LLC bought a new stake in Merit Medical Systems during the fourth quarter worth approximately $77,000. Finally, Harvest Fund Management Co. Ltd purchased a new stake in Merit Medical Systems during the third quarter valued at approximately $120,000. Institutional investors own 99.66% of the company's stock.

Insiders Place Their Bets

In other Merit Medical Systems news, CFO Raul Jr. Parra sold 12,451 shares of the business's stock in a transaction on Friday, February 28th. The shares were sold at an average price of $98.81, for a total value of $1,230,283.31. Following the sale, the chief financial officer now owns 24,201 shares in the company, valued at $2,391,300.81. The trade was a 33.97 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Fred P. Lampropoulos sold 31,320 shares of the firm's stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $103.86, for a total value of $3,252,895.20. Following the transaction, the chief executive officer now owns 1,086,028 shares of the company's stock, valued at approximately $112,794,868.08. The trade was a 2.80 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 109,132 shares of company stock worth $11,139,521 in the last three months. 3.70% of the stock is owned by company insiders.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.